drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous patient T cells genetically engineered to express a CD19-directed chimeric antigen receptor (CAR) incorporating CD3ζ with CD28 or 4-1BB co-stimulatory domains, enabling HLA-independent recognition and cytotoxic elimination of CD19-positive malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-specific chimeric antigen receptor containing CD3ζ and CD28 or 4-1BB co-stimulatory domains. The CAR enables HLA-independent binding to CD19 on B cells, triggering T-cell activation, proliferation, cytokine release, and cytotoxic killing of CD19-positive malignant B cells.
drug_name
Anti-CD19 CAR T-cell therapy
nct_id_drug_ref
NCT06369389